NGeneBio was founded in 2015 as a spin-off venture from Korea Telecom, develops in vitro diagnostics (IVD)/companion diagnostics (CDx) products and bioinformatics SW with cutting-of-edge technologies including next generation sequencing (NGS). The company launched NGS-based breast/ovarian cancer panel (BRCAaccuTest) with clinical analysis SW (NGeneAnalySys) and received CE-IVD and KFDA approval in 2017. Currently launched NGS panels and SW for solid tumor and hematological malignancies.
Business Needs: Direct Sales, Distributor/Agent/Representative, Licensing Agreements
Products to be exported: BRCAaccuTest (BRCA testing), HEMEaccuTest (hematologic malignancies), SOLIDaccuTest (solid tumors), NGeneAnalySys (clinical NGS analysis SW) and IDaccuTest (genetic profiling)